BioAtla, Inc. P/S Ratio
The price-to-sales (P/S) ratio tells you how many dollars investors pay for each dollar of a company's annual revenue. It is market capitalization divided by revenue over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/S means investors are paying more for each dollar of sales; because revenue is rarely negative, the ratio stays usable for companies that are not yet profitable. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- BioAtla, Inc. p/s ratio for fiscal 2022 was 29,909.4.
- Available history
- 2022-03-31 to 2022-03-31
- Data captured
Historical P/S Ratio
Annual P/S Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |